teamlab Biovortex Kyoto Set To Open This Fall
Summary
Opening this fall, teamLab Biovortex Kyoto will be the latest permanent immersive art museum by the acclaimed collectiveteamLab. Located nearKyotoStation, the museum is part of the city's broader urban revitalization initiative. This project aims to establish a dynamic cultural and creative hub, fostering a new synergy around art, youth, and innovation.
The concept behind 'Biovortex' suggests a swirling center of life and interconnectedness, themes deeply resonant with teamLab's artistic philosophy. Among the highlighted installations, 'Massless Amorphous Sculpture' stands out as a floating, shape-shifting entity, composed of foam-like material that maintains its form even when people enter it. This piece embodies teamLab's exploration of masslessness, creating a seamless blend of digital and tangible elements.
The immersive journey continues with other key works designed to challenge perception. 'Massless Suns and Dark Suns' presents a constellation of glowing orbs that shift based on human presence. As visitors widen their perception, dark spheres emerge, existing solely within the viewer's cognitive reality, making each experience uniquely personal. Another installation, 'Morphing Continuum,' is designed to stretch across both space and time, continuously regenerating as visitors immerse themselves within it. Additionally, 'Traces of Life' offers an interactive experience where visitors' movements create ephemeral trails, symbolizing the interconnectedness of individuals within the art space.
Unlike teamLab Planets Tokyo or teamLab Borderless, which feature seasonal themes, teamLab Biovortex Kyoto will showcase a rotating selection of immersive works, ensuring a constantly evolving experience for returning visitors. For more information, visit teamlab's officialwebsite.
teamLab Biovortex Kyoto20-1 Higashikujo Higashiiwamotocho,Minami Ward, Kyoto, 601-8006, Japan
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 hours ago
- Miami Herald
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)-a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal - Resetting the Genetic ClockDNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands-which act like gene "on/off" switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down - a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes)Neurodegenerative diseases like Alzheimer's and Parkinson'sAutoimmune diseases such as lupus and multiple sclerosisMetabolic conditions like Type 2 diabetesPremature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation - Rebuilding the Chromosomal ClockTelomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight RecoveryIn the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls - indicating functional recovery and metabolic improvement. 4. Oxidative Stress ReductionReactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival BenefitRoughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups - highlighting a systemic survival advantage. "These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging," said Erez Aminov, Chairman and CEO of Telomir. "While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore." "This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model," added Dr. Itzchak Angel, Chief Scientific Advisor. "The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases." Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya info@ 396-6723 SOURCE: Telomir Pharmaceuticals, Inc
Yahoo
3 hours ago
- Yahoo
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for EB103. EB103 is an innovative CD19-redirected ARTEMIS T-cell therapy designed to treat advanced B-cell Non-Hodgkin's Lymphomas (NHL). This next phase follows a successful first cohort, which reported no dose-limiting toxicities or serious adverse events, and even saw a complete response in one patient. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. The second cohort will test EB103 at a higher dose, aiming to further establish safety and efficacy. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s CEO, Cheng Liu, highlighted the therapy's potential to overcome limitations of conventional CAR-T treatments, particularly for high-risk groups such as patients with HIV-associated or CNS lymphomas, populations often excluded from current therapies. EB103 leverages proprietary ARTEMIS technology, allowing T-cells to more precisely target and destroy cancer cells. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s pipeline also includes EB104, targeting both CD19 and CD22 proteins found in most B-cell malignancies. The company's progress signals hope for broader, safer, and more effective immunotherapies for cancer and autoimmune disease patients. While we acknowledge the potential of ESLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESLA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Canadian supermodel Coco Rocha, 36, on her surprisingly 'effortless' beauty routine
Coco Rocha is legendary in the world of modelling. Nicknamed "The Queen of Pose," the Canadian supermodel has graced many of the world's most renowned catwalks (including one just three months postpartum) and magazine covers (she has at least 125 under her belt). Over the span of her 20-odd-year career, the Toronto native has become known for her creativity — and speed — at posing. More than a decade ago, she collaborated with photographer Steven Sebring on a book, Study of Pose: 1,000 Poses by Coco Rocha, in which she contorted herself into 1,000 different poses over a three-day photoshoot. While her posing is revered, Rocha says that among industry folks, she's best known for her sense of humour. "It's just lighthearted, joyful," the 36-year-old tells Yahoo Canada. "I want to have a good day. I don't want to be sulking and go, 'Oh, this is such a hard job. Isn't it so hard doing this thing called fashion?' I don't accept that. I really want to make people happy." Have you ever wondered what the world's most interesting, successful and talented people are adding to their shopping carts? Yahoo Canada's new series, , is exploring just that. From the supplement regime of professional athletes to supermodel-approved skincare, this is what celebrities actually spend their money on. I met Rocha (who's just as tall and beautiful as one would imagine) hours ahead of her appearance for the haircare brand OGX in Toronto. The supermodel was in town to introduce OGX's restorative Bond Protein Repair range, which she credited to her own hair health. "My job is to be a canvas," she says. "My job as this canvas is to be professional-looking. So, I need to take care of myself to the point that [makeup artists, hairdressers and designers] can play, they can destroy, they can make a Picasso, or they can destroy it." Hair repair products, like those from the OGX range, are the "stuff we need" to "keep being so playful," she explains. For the rest of her beauty routine, Rocha warns it's less interesting than one might think. "People are always like, there must be a routine. You must be doing things to stay healthy," she says. "Mostly, I just stay out of the sun and I drink a lot of water." Nevertheless, if there's one skincare product she does turn to, it's Drunk Elephant's Virgin Marula Luxury Face Oil. "I went to Sephora and I [asked] for something long-lasting and that would make me look hydrated," the Project Runway Canada host and judge recalls. "I love makeup, but I also just need my skin to live and breathe, and I want it to look like it's effortless. The [Drunk Elephant face oil] seems to be the trick for me." Beyond face oil and haircare, we asked Rocha what's in her Amazon cart, beauty cabinet and kitchen island these days. From her "fantastic" flameless candles to a sleek kettle worthy of her "museum," here are five things Canadian supermodel Coco Rocha is Adding to Cart. "[OGX] has some great shampoos and conditioners," the Project Runway Canada host says. "They have some leave-ins, the serum." All OGX hair products are "stuff we need" to have "playful," healthy hair. "I wear so much makeup, and I love makeup, but I'm at the point in my life where I also just need my skin to live and breathe, so I want it to look like it's effortless," Rocha tells Yahoo Canada. "The [Drunk Elephant Virgin Marula Luxury Facial Oil] seems to be the trick for me." It's long-lasting and hydrating, she says. "I usually have a sunscreen that's tinted, too, so I don't need to wear any foundation." "I'm building a house and my new kitchen is going to be black and white. My island is 18 feet. She's huge. It looks like a museum," Rocha says. "Everything is minimal; there's nothing on it. So everything that is on it has to be chic for my museum." According to the supermodel, this pour-over gooseneck kettle from Fellow passes the test. "I have two cats, a dog and many children," Rocha tells Yahoo Canada. Flameless candles are safe, convenient and kid-friendly. They're "actually fantastic." "I have a bar in my new house, a very big bar," Rocha tells Yahoo Canada. It's 18 feet. So she's going to have a Mixology [Bartender Kit]. If it's going to be up, it has to be pretty."
